Arcus Biosciences Inc (NYSE:RCUS)’s traded shares stood at 0.78 million during the latest session, with the company’s beta value hitting 0.88. At the last check today, the stock’s price was $17.87, to imply an increase of 3.10% or $0.54 in intraday trading. The RCUS share’s 52-week high remains $20.31, putting it -13.65% down since that peak but still an impressive 27.53% since price per share fell to its 52-week low of $12.95. The company has a valuation of $1.63B, with an average of 0.86 million shares in intraday trading volume over the past 10 days and average of 625.41K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Arcus Biosciences Inc (RCUS), translating to a mean rating of 1.58. Of 3 analyst(s) looking at the stock, 0 analyst(s) give RCUS a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -1.06.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Arcus Biosciences Inc (NYSE:RCUS) trade information
After registering a 3.10% upside in the latest session, Arcus Biosciences Inc (RCUS) has traded red over the past five days. The 5-day price performance for the stock is -2.04%, and 17.01% over 30 days. With these gigs, the year-to-date price performance is -6.45%. Short interest in Arcus Biosciences Inc (NYSE:RCUS) saw shorts transact 6.61 million shares and set a 12.52 days time to cover.
The extremes give us $20 and $44 for target low and target high price respectively. As such, RCUS has been trading -146.22% off suggested target high and -11.92% from its likely low.
Arcus Biosciences Inc (RCUS) estimates and forecasts
Looking at statistics comparing Arcus Biosciences Inc share performance against respective industry, we note that the company has outperformed competitors. Arcus Biosciences Inc (RCUS) shares are 21.30% up over the last 6 months, with its year-to-date growth rate higher than industry average at 21.69% against 17.50%. Revenue is forecast to shrink -12.80% this quarter before falling -8.30% for the next one. The rating firms project that company’s revenue will grow 115.70% compared to the previous financial year.
Revenue forecast for the current quarter as set by 10 analysts is 37.56M. Meanwhile, for the current quarter, a total of 10 analyst(s) estimate revenue growth to 30.84M.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -23.70% for the past 5-year period. While 2024 is set for a 23.20% return in earnings, projections for the next 5 years are at 7.80% annually.
RCUS Dividends
Arcus Biosciences Inc has its next earnings report out on 2024-Nov-06. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Arcus Biosciences Inc (NYSE:RCUS)’s Major holders
Arcus Biosciences Inc insiders hold 40.64% of total outstanding shares, with institutional holders owning 58.42% of the shares at 98.41% float percentage. In total, 58.42% institutions holds shares in the company, led by BLACKROCK INC. As of 2024-06-30, the company held over 9.76 million shares (or 11.3261% of shares), all amounting to roughly $148.69 million.
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 5.26 million shares, or about 6.099% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $80.07 million.
We also have iShares Core S&P Smallcap ETF and Fidelity Select Portfolios – Biotechnology as the top two Mutual Funds with the largest holdings of the Arcus Biosciences Inc (RCUS) shares. Going by data provided on Sep 30, 2024, iShares Core S&P Smallcap ETF holds roughly 3.43 shares. This is just over 3.75% of the total shares, with a market valuation of $62.12 million. Data from the same date shows that the other fund manager holds a little less at 2.14, or 2.34% of the shares, all valued at about 38.85 million.
